Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck

Table 2 Treatment-related events reported in ≥ 11% of patients in PACIFIC study arms and their rates in LUN 14-179 study¹

Event	Treatment arm and study
	Durvalumab in PACIFIC, n = 475		Placebo in PACIFIC, n = 234		Pembrolizumab in LUN 14-179
	Any grade	Grade 3/4	Any grade	Grade 3/4	Any grade	Grade 3/4
Any event	96.8%	30.5%	94.9%	26.1%
Cough	35.2%	0.4%	25.2%	0.4%	25.8%	1.1%
Fatigue	24%	0.2%	20.5%	1.3%	46.2%	4.3%
Dyspnea	22.3%	1.5%	23.9%	2.6%	21.5%	5.4%
Radiation pneumonitis	20.2%	1.5%	15.8%	0.4%
Diarrhea	18.5%	0.6%	19.7%	1.3%	15.1%	4.3%
Pyrexia	15.2%	0.2%	9.4%	0%
Nausea	14.3%	0%	13.2%	0%	15.1%	1.1%
Anorexia	14.3%	0.2%	12.8%	0.9%	17.2%	1.1%
Pneumonia	13.3%	4.4%	7.7%	3.8%
Pneumonitis	12.6%	1.9%	7.7%	1.7%	17.2%1	5.4%
Arthralgia	12.4%	0%	5.1%	0%	15.1%	1.1%
Pruritus	12.4%	0%	5.1%	0%	10.8%	0%
Rash	12.2%	0.2%	7.7%	0%	12.9%	1.1%
Constipation	11.8%	0.2%	8.5%	0%
Hypothyroidism	11.6%	0.2%	1.7%	0%	7.5%	0%

¹Grade ≥ 2.